High Dose Ilaprazole/Amoxicillin as First-Line Regimen forHelicobacter pyloriInfection in Korea

Abstract

Objective. The eradication rate ofHelicobacter pylori(H. pylori) following standard triple therapy has declined over the past few decades. This study has determined whether high dose dual therapy (PPI and amoxicillin) is adequate for eradicatingH. pyloriin Korea.Methods. This was an open-labeled study ofH. pyloriinfected treatment-naive patients. Subjects received dual therapy for 14 days: ilaprazole 40 mg tablets given twice a day and amoxicillin 750 mg tablets given 4 times a day. At the end of the therapy, the subjects visited the clinic to confirm compliance and monitor for any side effects. Subjects visited again after 4–6 weeks to confirmH. pyloristatus through a urea breath test.Results.The cure rate ofH. pyloriwas 79.3% (23 of 29) (95% confidence interval: 61.6–90.2) in the intention-to-treat analysis and 82.1% (23 of 28) in the per-protocol analysis. Compliance rates were high (96.6%) and side effects were minimal and tolerable.Conclusion.A high dose of ilaprazole + amoxicillin was ineffective as the first-line therapy for eradicatingH. pyloriin Korea. Future studies should focus on intragastric pH measurements and assess amoxicillin resistance.